Lung SurgeryNCT07241286
Evaluation of the Effectiveness of Enhanced Recovery After Surgery (ERAS) Program in Pediatric Lung Surgery
An observational study of Lung Surgery and Enhanced Recovery After Surgery, ERAS, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
This study aims to evaluate the clinical effectiveness of the Enhanced Recovery After Surgery (ERAS) program for pediatric lung surgery at our institution. Read more about this study
- Who is it for?
- Ages 0 to 18 years
- Conditions the study is for
- Lung Surgery, Enhanced Recovery After Surgery, ERAS, Pediatric
- What is being tested?
- Enhanced Recovery After Surgery, ERAS
- Type of treatment
- Pill or oral medicine
- How many people
- 100 participants
- Where
- 1 siteTaiwan
- Study dates
- 5 Jun 2025to 28 Feb 2030
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Pediatric patients aged 0 to 18 years who underwent lung surgery at our institution. Eligible procedures were identified using treatment thoracoscopic lobectomy, thoracoscopic wedge or partial resection, and thoracoscopic segmentectomy.
Who may be able to join
- Children who underwent lung surgery at our hospital's Division of Pediatric Surgery
Who cannot join
- Patients who underwent multiple surgeries (including surgeries other than lung surgery) during the same hospitalization
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This study aims to evaluate the clinical effectiveness of the Enhanced Recovery After Surgery (ERAS) program for pediatric lung surgery at our institution.
Read the detailed description
Using a prospective cohort design, we will observe pediatric patients undergoing lung surgery following the implementation of the ERAS program as standard practice. Outcomes will be compared with a historical control group (2014-2023) to assess whether ERAS reduces hospital length of stay, lowers postoperative complication rates, accelerates recovery, and decreases healthcare costs.
- Being tested
- Enhanced Recovery After Surgery, ERAS
- Keywords
- Thoracoscopic, Partial resection, pediatric, infant, ERAS, VATS, lobectomy, segmentectomy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Enhanced Recovery After Surgery, ERASOther
During the study period, all enrolled patients will be managed according to our institution's consensus checklist for pediatric lung surgery ERAS care. This includes ERAS education, preoperative assessment, fasting guidance, prophylaxis for nausea and vomiting, standardized anesthesia and surgical protocols, preference for minimally invasive surgery, multimodal postoperative analgesia, and encouragement of early oral intake and mobilization.
| Study group | Role | What they receive |
|---|---|---|
| Enhanced Recovery After Surgery, ERAS | During the study period, all enrolled patients will be managed according to our institution's consensus ERAS checklist for pediatric lung surgery. Receives: Other: Enhanced Recovery After Surgery, ERAS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Length of hospital stay
Number of days from index operation to hospital discharge
Measured: Up to 30 days after surgery.
Secondary outcomes (9)
Postoperative complications
Incidence of postoperative complications, including prolonged air leak, pneumonia, surgical site infection, and other procedure-related events.
Measured: Within 30 days after surgery.
Duration of urinary catheter placement
Number of days with indwelling urinary catheter postoperatively.
Measured: From date of surgery to catheter removal (up to 30 days)
Duration of chest tube drainage
Number of days with thoracic drainage tube postoperatively.
Measured: From date of surgery to chest tube removal (up to 30 days).
Intensive care unit stay
Number of days in ICU after surgery.
Measured: From date of ICU admission to transfer out (up to 30 days).
Postoperative pain
Pain intensity assessed by numeric rating scale (NRS)
Measured: Daily assessment up to 7 days postoperatively.
Postoperative analgesic use
Total analgesic consumption.
Measured: Daily assessment up to 7 days postoperatively.
30-day readmission or emergency department visit
Incidence of unplanned readmission or emergency department visit within 30 days after discharge.
Measured: Within 30 days post-discharge.
Time to resumption of oral intake
Interval from surgery to first tolerated oral feeding.
Measured: From date of surgery to initiation of oral intake (up to 7 days).
Hospital cost
Total hospitalization cost during the index admission.
Measured: From date of admission to discharge, up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2025
- Study start5 Jun 2025
- Primary completion28 Feb 2030 (estimated)
- Study completion28 Feb 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Lung SurgeryStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07241286
- Sponsor's protocol ID
- 202504141RINE
- Status last verified
- Aug 2026
- First submitted
- 2 Oct 2025
- Last updated
- 17 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Children 2021, 8(12), 1154
Ha D, Harris KT, Brockel MA, Rove KO. The role of enhanced recovery after surgery (ERAS) in promoting quality improvement and patient safety in pediatric urology. Front Urol. 2023 Sep 28;3:1275276. doi: 10.3389/fruro.2023.1275276. eCollection 2023.
PubMed 40778051
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effectiveness of Enhanced Recovery After Surgery (ERAS) Program in Pediatric Lung Surgery
- ClinicalTrials.gov ID
- NCT07241286
- Acronym / sponsor ID
- 202504141RINE
- Keywords
- Thoracoscopic, Partial resection, pediatric, infant, ERAS, VATS, lobectomy, segmentectomy
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 5 Jun 2025 (actual)
- Primary completion
- 28 Feb 2030 (estimated)
- Study completion
- 28 Feb 2030 (estimated)
- First posted
- 21 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the clinical effectiveness of the Enhanced Recovery After Surgery (ERAS) program for pediatric lung surgery at our institution.
Detailed description
Using a prospective cohort design, we will observe pediatric patients undergoing lung surgery following the implementation of the ERAS program as standard practice. Outcomes will be compared with a historical control group (2014-2023) to assess whether ERAS reduces hospital length of stay, lowers postoperative complication rates, accelerates recovery, and decreases healthcare costs.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Month
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Enhanced Recovery After Surgery, ERAS | – | Other: Enhanced Recovery After Surgery, ERASDuring the study period, all enrolled patients will be managed according to our institution's consensus ERAS checklist for pediatric lung surgery. |
Who may qualify
- Ages
- 0 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Pediatric patients aged 0 to 18 years who underwent lung surgery at our institution. Eligible procedures were identified using treatment thoracoscopic lobectomy, thoracoscopic wedge or partial resection, and thoracoscopic segmentectomy.
Key inclusion criteria (1 listed)
- Children who underwent lung surgery at our hospital's Division of Pediatric Surgery
Key exclusion criteria (1 listed)
- Patients who underwent multiple surgeries (including surgeries other than lung surgery) during the same hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Enhanced Recovery After Surgery, ERASDuring the study period, all enrolled patients will be managed according to our institution's consensus checklist for pediatric lung surgery ERAS care. This includes ERAS education, preoperative assessment, fasting guidance, prophylaxis for nausea and vomiting, standardized anesthesia and surgical protocols, preference for minimally invasive surgery, multimodal postoperative analgesia, and encouragement of early oral intake and mobilization. | Other | Enhanced Recovery After Surgery, ERAS |
Primary outcome
Length of hospital stay
Time frame: Up to 30 days after surgery.
Number of days from index operation to hospital discharge
9 secondary outcomes
Postoperative complications
Time frame: Within 30 days after surgery.
Duration of urinary catheter placement
Time frame: From date of surgery to catheter removal (up to 30 days)
Duration of chest tube drainage
Time frame: From date of surgery to chest tube removal (up to 30 days).
Intensive care unit stay
Time frame: From date of ICU admission to transfer out (up to 30 days).
Postoperative pain
Time frame: Daily assessment up to 7 days postoperatively.
Postoperative analgesic use
Time frame: Daily assessment up to 7 days postoperatively.
30-day readmission or emergency department visit
Time frame: Within 30 days post-discharge.
Time to resumption of oral intake
Time frame: From date of surgery to initiation of oral intake (up to 7 days).
Hospital cost
Time frame: From date of admission to discharge, up to 30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2026.
- BackgroundChildren 2021, 8(12), 1154
- Background: PubMed 40778051Ha D, Harris KT, Brockel MA, Rove KO. The role of enhanced recovery after surgery (ERAS) in promoting quality improvement and patient safety in pediatric urology. Front Urol. 2023 Sep 28;3:1275276. doi: 10.3389/fruro.2023.1275276. eCollection 2023.
- Individual participant dataSharing planned: No
Related trials for Lung Surgery
RecruitingPhase 1
Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia
Renal Failure Congenital, Congenital Renal Anomaly Nos
Active, not recruitingPhase 2
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
RecruitingPhase 3
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Non Small Cell Lung Cancer
Not yet recruiting
Individualized Inspired Oxygen Fraction Titration During Lung Surgery (iOXY-LUNG)
Postoperative Complications
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Surgery and Enhanced Recovery After Surgery, ERAS, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Length of hospital stay (time frame: Up to 30 days after surgery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07241286, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.